104 related articles for article (PubMed ID: 1646217)
1. The endocrine effects of long-term treatment with mifepristone (RU 486).
Lamberts SW; Koper JW; de Jong FH
J Clin Endocrinol Metab; 1991 Jul; 73(1):187-91. PubMed ID: 1646217
[TBL] [Abstract][Full Text] [Related]
2. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
[TBL] [Abstract][Full Text] [Related]
3. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
[TBL] [Abstract][Full Text] [Related]
4. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.
Gaillard RC; Riondel A; Muller AF; Herrmann W; Baulieu EE
Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3879-82. PubMed ID: 6328529
[TBL] [Abstract][Full Text] [Related]
5. Mifepristone (RU 486) treatment of meningiomas.
Lamberts SW; Tanghe HL; Avezaat CJ; Braakman R; Wijngaarde R; Koper JW; de Jong H
J Neurol Neurosurg Psychiatry; 1992 Jun; 55(6):486-90. PubMed ID: 1619417
[TBL] [Abstract][Full Text] [Related]
6. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
7. Adrenal function under long-term raloxifene administration.
Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
[TBL] [Abstract][Full Text] [Related]
8. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects.
Laue L; Lotze MT; Chrousos GP; Barnes K; Loriaux DL; Fleisher TA
J Clin Endocrinol Metab; 1990 Dec; 71(6):1474-80. PubMed ID: 2172280
[TBL] [Abstract][Full Text] [Related]
9. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
[TBL] [Abstract][Full Text] [Related]
10. Estrogens and the hypothalamo-pituitary-adrenal axis in man: evidence for normal feedback regulation by corticosteroids.
Baumann G
J Clin Endocrinol Metab; 1983 Dec; 57(6):1193-7. PubMed ID: 6630413
[TBL] [Abstract][Full Text] [Related]
11. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception.
Glasier A; Thong KJ; Dewar M; Mackie M; Baird DT
N Engl J Med; 1992 Oct; 327(15):1041-4. PubMed ID: 1522839
[TBL] [Abstract][Full Text] [Related]
12. Transient inhibition of RU 486 antiglucocorticoid action by dexamethasone.
Raux-Demay MC; Pierret T; Bouvier d'Yvoire M; Bertagna X; Girard F
J Clin Endocrinol Metab; 1990 Jan; 70(1):230-3. PubMed ID: 2152931
[TBL] [Abstract][Full Text] [Related]
13. Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea.
Biller BM; Federoff HJ; Koenig JI; Klibanski A
J Clin Endocrinol Metab; 1990 Feb; 70(2):311-7. PubMed ID: 2153693
[TBL] [Abstract][Full Text] [Related]
14. Familial and iatrogenic cortisol receptor resistance.
Lamberts SW; Koper JW; Biemond P; den Holder FH; de Jong FH
Cancer Res; 1989 Apr; 49(8 Suppl):2217s-2219s. PubMed ID: 2539256
[TBL] [Abstract][Full Text] [Related]
15. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism.
Garrel DR; Moussali R; De Oliveira A; Lesiège D; Larivière F
J Clin Endocrinol Metab; 1995 Feb; 80(2):379-85. PubMed ID: 7888013
[TBL] [Abstract][Full Text] [Related]
16. Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone.
Wang JD; Shi WL; Zhang GQ; Bai XM
Contraception; 1994 Mar; 49(3):245-53. PubMed ID: 8200218
[TBL] [Abstract][Full Text] [Related]
17. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity.
van Haarst AD; Oitzl MS; Workel JO; de Kloet ER
Endocrinology; 1996 Nov; 137(11):4935-43. PubMed ID: 8895366
[TBL] [Abstract][Full Text] [Related]
18. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
19. Mifepristone: treatment of Cushing's syndrome.
Sartor O; Cutler GB
Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
[TBL] [Abstract][Full Text] [Related]
20. The new steroid analog RU 486 inhibits glucocorticoid action in man.
Bertagna X; Bertagna C; Luton JP; Husson JM; Girard F
J Clin Endocrinol Metab; 1984 Jul; 59(1):25-8. PubMed ID: 6327758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
